Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DC/CIK therapy in advanced esophagus cancer
NCT02693236Phase 2Unknown
- Sponsor
- Academy of Military Medical Sciences
- Start
- Aug 2014
- Primary completion
- Aug 2016
- Countries
- 1
01
Overview
A Phase 2 trial of adenovirus-transfected autologous dendritic cell vaccine (MUC1/Survivin) in esophageal cancer, sponsored by Academy of Military Medical Sciences. Status: unknown.
02
Drugs
adenovirus-transfected autologous dendritic cell vaccine (MUC1/Survivin)
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on NCT02693236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02693236.